Biopharmaceutical News and Research

RSS

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

caprotec bioanalytics GmbH announced today that the United States Patent Office has issued patent No. US9,034,789 covering its revolutionary Capture Compound Mass Spectrometry (CCMS) technology.

20 Aug 2015

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax.

19 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

CASI reports financial results for second quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and six months ended June 30, 2015.

14 Aug 2015

RealTime Dynamix: New monthly service launched for pharmaceutical markets

Spherix Global Insights announces the launch of RealTime Dynamix, its new monthly service developed to keep clients on the pulse in highly dynamic specialty markets.

13 Aug 2015

$AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion$

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

12 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC.

11 Aug 2015

Turing Pharmaceuticals completes $90 million Series A financing

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, today announced the completion of its Series A financing. The $90 million round was led by Martin Shkreli, Founder & Chief Executive Officer.

10 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round.

6 Aug 2015

LifeBond announces closure of $27M Series D preferred equity investment

LifeBond, a leader in the development of bio-surgical medical devices for tissue repair, announced today it has closed a $27M Series D preferred equity investment. Participants in the round include Pitango Venture Capital, Adams Street Partners, Sino Biopharmaceutical Ltd., and all existing investors.

5 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

4 Aug 2015

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).

3 Aug 2015

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC.

3 Aug 2015

Biopharmaceutical News and Research

DelMar closes on $2.6 million registered direct placement

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

CASI reports financial results for second quarter 2015

RealTime Dynamix: New monthly service launched for pharmaceutical markets

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

Ardelyx reports net income of $9.0 million for second quarter 2015

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Turing Pharmaceuticals completes $90 million Series A financing

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

LifeBond announces closure of $27M Series D preferred equity investment

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Event guide: World ADC San Diego eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News